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ABSTRACT
Current guidelines published by the Centers for Disease Control and Prevention
(CDC) and American Academy of Pediatrics (AAP) recommend empiric antibiotics for
all neonates born to mothers with a diagnosis of chorioamnionitis due to the risk of
early onset sepsis (EOS). EOS is difficult to diagnose due to nonspecific symptoms and
a lack of reliable tests, can progress quickly, and is potentially fatal or have
neurodevelopmental consequences for survivors.
Antibiotics are frequently prescribed in the hospital and are lifesaving in the
setting of a serious infection. Conversely, overuse of antibiotics has potential negative
effects to individuals and the population as a whole. Antibiotic resistant infections are a
consequence of antibiotic misuse, are costly and difficult to treat, and pose a risk to
patients hospitalized.
To examine this problem at The University of Vermont Medical Center
(UVMMC) a retrospective chart review was preformed. Data on the maternal risk
factors associated with EOS were collected in addition to clinical characteristics of their
neonates and entered into a neonatal early onset sepsis (NEOS) calculator to determine
the specific risk of infection to each infant. Treatment of the infant was compared to the
NEOS calculator and CDC recommendations. Using posterior probability to determine
a more specific risk profile better targets antibiotic therapy to ensure all infants that
need treatment receive it, while reducing the number of infants treated empirically.
UVMMC currently treats 78% of infants according to CDC guidelines. Use of
the NEOS calculator would reduce antibiotic treatment to 18% of term neonates born to
mothers with a diagnosis of chorioamnionitis. Using a new tool to determine risk of
EOS may safely reduce the number of infants receiving antibiotic treatment.
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CHAPTER 1: INTRODUCTION
1.1. Background and Significance
Early onset sepsis (EOS) is a systemic bacterial infection that affects neonates
with onset in the first 72 hours following birth (Polin, 2012; Weston et al., 2011; Cotten,
2015). EOS is among the top 10 causes of neonatal and infant death. Of these cases,
10.9% are fatal, accounting for 390 deaths annually (Weston et al., 2011). Hearing loss,
seizures, and neurodevelopmental abnormalities can affect survivors of EOS (Weston et
al., 2011). EOS is associated with vertical transmission from the mother to the neonate
during delivery from the normal flora of the birth canal or pathologic infection of the
amniotic fluid and chorionic membranes, referred to as chorioamnionitis. The most
common pathogens of EOS are Group B streptococcus (GBS) and Escherichia coli (E.
coli) (Polin, 2012; Bizzarro et al., 2015).
Risk factors for EOS include preterm delivery, maternal GBS colonization,
rupture of membranes (ROM) greater than 18 hours, maternal fever, maternal
leukocytosis, maternal tachycardia, uterine tenderness, foul odor of amniotic fluid, or a
formal diagnosis of chorioamnionitis. Chorioamnionitis alone is a major risk factor for
EOS and is associated with a two to three fold increased risk to the term neonate
(Mukhopadhyay & Puopolo, 2012). The Centers for Disease Control and Prevention
(CDC) and American Academy of Pediatrics (AAP) both recommend that 100% of
neonates born to a mother with a diagnosis of chorioamnionitis be treated empirically
with broad spectrum antibiotics for 48 hours pending negative laboratory tests (Benitz et
al., 2015; Verani et al., 2010; COFN, 2011).
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Using the diagnosis of chorioamnionitis to determine neonatal management is
problematic due to a variable definition that does not follow strict criteria in current
practice (Benitz et al., 2015). Early studies that linked chorioamnionitis to EOS used
strict diagnostic criteria for chorioamnionitis requiring one to two clinical findings in
addition to intrapartum maternal fever (Benitz et al., 2015), such as maternal or fetal
tachycardia, uterine tenderness, foul odor of the amniotic fluid, or maternal leukocytosis
(Verani et al., 2010). Often, in clinical practice, maternal fever is used as a surrogate for
the diagnosis of chorioamnionitis (Mukhopadhyay & Puopolo, 2012; Benitz et al., 2015;
Malloy, 2014). The rate of culture proven EOS in infants born to mothers with clinical
chorioamnionitis was found in several studies to be low; ranging from 0.47 to 1.24%
(Jackson et al., 2004; Jackson, Rawiki, Sendelbach, Manning, & Engle, 2012; Kiser,
Nawab, McKenna, & Aghai, 2014). Yet, current in treatment guidelines, maternal
chorioamnionitis remains a key component of management decisions in term neonates.
Decisions regarding the need for treatment with systemic antibiotics are guided
by algorithms published by the CDC (Verani et al., 2010) and have been adopted by the
AAP (Polin, 2012; Brady & Polin, 2013). Algorithms are used to assist in timely
treatment decisions because an immature immune system at the time of birth and no test
that can reliably rule in or rule out EOS makes a definitive diagnosis of EOS difficult.
The vague presenting signs and symptoms of EOS may delay treatment initiation and
increase disease related mortality (Cotten & Smith, 2013). Subsequently, clinicians may
have a low threshold for initiating treatment of suspected EOS based on maternal risk
factors (Polin, 2012).
2

A 40% decline in neonatal EOS cases has been observed following the initiation
of universal GBS screening and intrapartum antibiotic prophylaxis (IAP) for GBS
positive women (Mukhopadhyay, Eichenwald, & Puopolo, 2013). Benitz et al. (2015)
reported an 85% reduction of culture proven GBS sepsis from the early 1990s to 2010
through the adoption of obstetrical prevention strategies of IAP. Current treatment
algorithms were developed prior to widespread GBS screening and IAP (Puopolo et al.,
2011); a population with a much higher incidence of EOS than the current population.
Thus, the algorithms are limited in their ability to precisely determine which neonates
would benefit from empiric antibiotic treatment in present day. Despite the decreased
incidence of EOS, empiric treatment based on risk factors remains the standard of care
(Benitz et al., 2015) and result in antibiotic treatment of large numbers of uninfected
newborns (Puopolo et al., 2011)
The use of outdated algorithms overestimates the risk of EOS and leads to
overtreatment and unnecessary antibiotic use in neonates (Puopolo et al., 2011). The use
of unnecessary antibiotics has been shown to have serious sequelae such as potential
toxicities (Kiser, Nawab, McKenna, & Aghai, 2014, Cotten, 2015), development of
antibiotic resistant organisms (Smith, M’ikanatha, & Read, 2015), and more recently
concerns about the effects on the neonate’s developing microbiome (Madan, Farzan,
Hibberd, & Karagas, 2012). Further, antibiotics should be used with caution because the
long term effects of antibiotics on neonate metabolism and immune programming are not
fully understood (Ajslev, Andersen, Gamborg, Sørensen, & Jess, 2011). Kiser et al.
(2014) found that infants receiving prolonged antibiotic therapy incur additional invasive
3

procedures such as lumbar puncture, central and peripheral lines, or umbilical
catheterization that lead to longer hospital stays and higher costs. Additionally, there are
psychological costs such as disruption of maternal bonding (Escobar et al., 2014).
Puopolo & Escobar et al. (2013) developed a neonatal early onset sepsis
(NEOS) calculator that uses the relative contributions of EOS risk factors to develop an
individualized infection probability that could decrease the number of neonates who
receive empiric antibiotic treatment for EOS. By using recent prevalence data for EOS
and the relative contribution of each risk factor, a more precise management strategy is
achieved for individual neonates, which has the potential to reduce antibiotic exposure
without compromising safety. Shakib et al. (2015) compared current AAP and CDC
guidelines to NEOS calculator. Application of the NEOS calculator was estimated to
reduce empiric antibiotic use by 65% of the study population (Shakib, Buchi, Smith, &
Young, 2015). Further, Escobar et al. (2014) estimated that application of a model, which
takes into account the relative risk factors of individual neonates, could reduce antibiotic
exposure in 80,000 to 240,000 neonates in the US annually. Adoption of the NEOS
calculator and a more precise risk stratification model to treat suspected EOS has the
potential to decrease unnecessary antibiotic exposure, reduce health care costs, minimize
antibiotic resistance, and lead to better health outcomes for neonates.

1.2. Advanced Practice Nurse Competencies
The following discussion addresses how this thesis fulfills the 2013 advanced
practice nurse (APN) competencies (Thomas, 2012). The core competencies of scientific
4

foundation and practice inquiry are specifically addressed. The scientific foundation
competency involves critically analyzing data and using evidence to improve practice.
The aim of this thesis is to translate research, observation, and knowledge into practice by
applying new practice approaches to a vulnerable population. Observation of a clinical
problem paired with physiologic understanding generated the base of the research
question. Extensive research allowed for exploration of the current knowledge about the
topic and narrowing of the particular question of interest. The practice inquiry
competency involves the APN being a leader in the translation of new knowledge into
practice. This thesis will apply clinical investigative skills using a systematic chart review
to add to the body of knowledge leading to improved health outcomes. Additionally, this
research will be presented to hospital staff and submitted for publication that will
improve collaboration between disciplines, improve patient outcomes, and advance the
role of the APN.

1.3. Purpose
The aim of this study is to determine if the application of a NEOS calculator
(Kaiser Permanente, 2015) to generate treatment recommendations would reduce
antibiotic exposure of term neonates born to mothers with a diagnosis of chorioamnionitis
at an academic medical center in the northeastern United States. A secondary aim is to
retrospectively evaluate provider adherence to previously published guidelines for the
treatment of neonates born to mothers with chorioamnionitis published by the CDC and
adopted by the AAP.
5

1.4. Hypotheses
The a priori hypothesis was that the application of the NEOS calculator would
reduce the number of term neonates born to mothers with a diagnosis of chorioamnionitis
that receive empiric antibiotics. We hypothesized that there were neonates not managed
according to current CDC guidelines in the study population.

1.5. Significance
This study examined a more sophisticated and current EOS management tool to
determine if it could reduce empiric antibiotic use while maintaining patient safety and
achieve improved patient outcomes. Study results will inform future practice regarding
the treatment of EOS and may result in a reduction of empiric antibiotic use in neonates
born to mothers with a diagnosis of chorioamnionitis. Further, the findings of this study
provide baseline data of antibiotic administration using current treatment guidelines that
were in place for the year 2014 at an academic medical center in the northeastern United
States. Areas of antibiotic administration that might be improved upon in the neonatal
population are reviewed.
The use of antibiotics in the neonatal intensive care unit (NICU) is an area under
consideration for quality improvement initiatives through the Vermont Oxford Network
(Soll & Edwards, 2015). Study findings will serve as pilot data for a larger, multicenter
quality initiative examining the empiric use of antibiotics for suspected EOS treatment.

6

Through presentation of the research findings clinicians may consider current practice in
the context of the most current research and improve antibiotic stewardship.
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CHAPTER 2: LITERATURE REVIEW
The following chapter will describe the current literature surrounding antibiotic
use in the NICU and opportunities for improvement. EOS is a difficult diagnosis to make
clinically or with laboratory tests, so treatment guidelines based on risk factors are used
in practice. However, the guidelines were developed prior to the widespread use of IAP
that have significantly lowered the rates of EOS compared to when the guidelines were
developed. The risk factor that leads to the most broad empiric antibiotic use is the
maternal diagnosis of chorioamnionitis. Chorioamnionitis has variable diagnostic criteria
that confer a variable amount of risk to neonates. Antibiotic use is not benign with
potential long term health consequences to individuals and overuse is a cause of
antibiotic resistance. Finally, a new model that uses continuous rather than dichotomized
data and the relative contributions of each risk factor is presented and its ability to stratify
risk to target empiric therapy to decrease antibiotic use is described.

2.1. Antibiotic Use in the NICU
The most prescribed medication class in American NICUs are antibiotics
(Cantey, Wozniak, & Sánchez, 2015; Grohskopf et al., 2005). In a survey of 29 NICUs
43% of patients were receiving antibiotics (Grohskopf et al., 2005). Cantey et al. (2015)
found that 72% of neonates in a level three NICU in Texas had one or more courses of
antibiotics with an average of 5.7 antibiotic treatment days per neonate. In the study by
Cantey et al. (2015) less than 7% of antibiotic use was directed toward proven infection.
Antibiotics are frequently used and often unavoidable in the NICU. Neonates have subtle
8

clinical presentations of infection, are at high risk of infection, and potentially severe
outcomes due to infection (Cotten, 2016; Magsarili, Girotto, Bennett, & Nicolau, 2015).
Antibiotic use rates and prescribing patterns vary considerably between NICUs.
In a study of 44 French NICUs there was an average of nine different dosing regimens for
each of the 41 antibiotics examined (Leroux et al., 2015). During 2013, California NICUs
with similar rates of proven infection, mortality, and surgical volume had a 40-fold
variation in antibiotic prescribing practice (from 2.4% to 97.1% of patient days)
(Schulman et al., 2015). Schulman et al. (2015) concluded that the variation between
prescribing practices differed only in how practitioners respond to clinical situations of
suspected infection. The discrepancy in antibiotic use rates, without a difference in
neonatal outcome supports antibiotic overuse (Schulman et al., 2015) and represents an
opportunity for antibiotic stewardship.
The majority of antibiotic use in the NICU is for suspected infection. Only 5%
of antibiotic use was for culture proven infection (Cotten, 2016), while 94% was empiric
use for suspected infection (Cantey et al., 2015). In a prospective surveillance study of
antibiotic use the majority (63%) of all antibiotics during the study period were initiated
for suspected EOS that was subsequently ruled out by a sterile blood culture at 48 hours
(Cantey et al., 2015). Despite documentation to discontinue antibiotics when the blood
culture was negative and infection was no longer clinically suspected antibiotics were
inadvertently continued 68% of the time accounting for 12% of total antibiotic use during
the study period (Cantey et al., 2015).
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Although empiric antibiotics are a component of early initiation of treatment for
neonates with culture proven infection, it is not clear how many asymptomatic neonates
with negative blood cultures are exposed to unnecessary antibiotics through this practice
(Braun, Bromberger, Ho, & Getahun, 2015). Conversely, the potential ramification of
decreasing the number neonates who receive empiric antibiotic therapy is the failure to
achieve early treatment for true infections (Benitz et al., 2015). The risk of untreated
infection needs to be balanced against the potential adverse effects of antibiotic treatment
in neonates with sterile blood cultures (Tripathi, Cotten, & Smith, 2012).

2.2. Early Onset Sepsis
2.2.1. Definition and diagnosis. EOS is a systemic bacterial infection that
affects neonates in the first 72 hours following birth (Cotten, 2015; Polin & COFN, 2012;
Weston et al., 2011). The presentation of EOS varies widely, from clear clinical illness to
subtle and nonspecific signs. Any change from a neonate's usual pattern of activity,
breathing, or feeding could potentially be an indication of EOS, or could be attributable
to the normal transition to extra-uterine life. A definitive diagnosis of EOS is the isolation
of a pathogen from the blood stream. However, a blood culture cannot be relied upon for
diagnosis because culture confirmed cases represent a small fraction of the EOS burden,
and only 5% of all clinically suspected cases are culture confirmed (Weston et al., 2011).
A blood culture is an unreliable diagnostic because of high false negative rates resulting
from either inadequate blood volume or IAP suppressing bacterial growth in the sample
(Escobar et al., 2000). Conversely, a portion of clinical EOS diagnoses include
10

syndromes that are noninfectious, such as complications of birth and metabolic instability
contributing to the difficulty of the EOS diagnosis (Weston et al., 2011).
Clinical signs are the most reliable diagnostic for EOS (92% sensitive and 53%
specific) (Escobar et al., 2000). The majority of infants who develop EOS are
symptomatic in the first 12 hours of life (Duvoisin, Fischer, Maucort-Boulch, &
Giannoni, 2014). A neonate that is asymptomatic during the first 12 hours of life was
found to be significantly protective for EOS (mothers with IAP, OR: 0.36 (95% CI 0.140.96); mothers without IAP OR: 0.26 (95% CI 0.11-0.63)) (Escobar et al., 2000). The
proven infection rate for clinically asymptomatic neonates was 0.9% while the critically
ill proven infection rate was 10.0% (Escobar et al., 2000).
Physical exam findings have been shown to be a safe and effective way to
reduce the use of antibiotics in neonates suspected to have EOS. In a historically
controlled study, Duvoisin et al. (2014) examined an EOS practice change with the aim
of reducing the number of diagnostic tests. Their study population was neonates with a
gestational age greater than or equal to 35 weeks, risk factors for EOS (inadequate IAP,
ROM greater than 18 hours, maternal fever, or less than 37 weeks gestation), and
intravenous antibiotic treatment in the first week of life. The authors examined a practice
change that neonates were examined every eight hours by providers and vital signs every
4 hours for the first 24 hours of life and every 8 hours for the second 24 hours. This was
compared to a standard of care consisting of complete blood count (CBC) with manual
differential count and C- reactive protein (CRP) performed in all infants born to mothers
with one risk factor and vital signs measured in the same manner. The number of
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neonates treated for suspected EOS decreased from 2.1% to 1.7% (p = 0.09) after
implementing the new protocol and the use of CRP and CBCs were reduced by 91% and
30%, respectively (Duvoisin et al., 2014). The authors found that detection of illness and
initiation of antibiotics was effective using direct observation for clinical EOS symptoms.
Foregoing traditional blood tests resulted in no differences in duration of hospital stay or
proportions if infants needing respiratory or cardiovascular support. Following the
author's practice change the first dose of antibiotics was administered 6.2 hours earlier
than in the standard of care. The findings suggest that eliminating routine blood tests and
enhancing physical exam appears to be safe, results in earlier initiation of treatment, and
decreases the number of neonates receiving antibiotics, while eliminating many costly
and painful laboratory tests.
Cantoni et al., (2013) also compared physical exam alone to physical exam with
laboratory tests in a prospective, sequential, population based study of term infants in
north-eastern Italy. The parameters of the standardized physical exam included skin
appearance (pink, pale, mottled, or cyanotic), respiratory rate (above or below 60 per
minute), and respiratory retractions (yes or no) measured every one to six hours in the
first 48 hours of life. Laboratory tests with standardized physical exam did not offer any
advantage over standardized physical exam alone (Cantoni, Ronfani, Da Riol, &
Demarini, 2013). In this study antibiotic initiation decreased from 1.2% to 0.5% (p <
0.001), and there was a 91% relative reduction in the use of blood cultures (Cantoni et al.,
2013). During the study periods there was no difference in need for respiratory support or
length of hospital stay. Presence of clinical signs was the most frequently documented
12

reason for starting antibiotics followed by presence of risk factors and then abnormal
CBC or CRP (Cantoni et al., 2013).
2.2.2. Incidence of EOS. Current incidence of EOS is between 0.5 and 1.2 per
thousand live births (Escobar et al., 2014). Weston et al. (2011) used state vital records of
live birth data to calculate the EOS rate to be 0.77 per thousand live births in 2005, which
remained stable at 0.76 per thousand live births in 2008. Weston et al. (2011)
demonstrated a disparate disease burden based on race and prematurity. Black preterm
neonates had the highest incidence (5.14 per thousand live births) and a fatality rate of
24.4% of cases (Weston et al., 2011). The group with the lowest incidence of EOS was
non-black term neonates, 0.40 per thousand live births and fatality rate of 1.6% (Weston
et al., 2011). Preterm neonates accounted for 47.3% of all EOS cases and 92.3% of deaths
from EOS (Weston et al., 2011). The estimated national burden of culture positive cases
was 3320 cases annually (Weston et al., 2011).
Incidence of EOS has declined more than 80% from 1990 to 2008 corresponding
to universal screening and treatment for GBS that was first introduced in 1996 and
updated in 2002 and 2010 (Cotten, 2015; Weston et al., 2011). Escobar et al. (2000)
found that neonates born to mothers treated with IAP were less likely to be symptomatic,
need assisted ventilation, or have bacterial infection. Nearly half (48%) of women had at
least one dose of antibiotics during labor (Braun et al., 2015). The current treatment
guidelines for EOS were developed IAP use was widespread (Cantey & Patel, 2014)
therefore neglecting the protective properties of that practice change.
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Despite the decreased incidence of EOS empiric treatment of neonates remains
high. Although the frequency of neonatal bacterial infection ranges from 0.001 to
0.005%, the percentage of neonates treated with systemic antibiotics is between 4.4 and
10.5% (Escobar et al., 2000). The short term economic burden of caring for neonates with
EOS is estimated to be $700 million in the United States annually (Wynn et al., 2014).
2.2.3. Risk factors for EOS. Perinatal risk factors for EOS are neither sensitive
nor specific. Identified risk factors for EOS include preterm delivery, maternal GBS
colonization, premature ROM greater than 18 hours, maternal signs of infection: fever
greater than 100.4ºF (38ºC), maternal leukocytosis (total blood leukocyte count greater
than 15,000 cells/µL), maternal tachycardia (greater than 100 beats per minute), uterine
tenderness, foul odor of amniotic fluid, or a diagnosis of chorioamnionitis (Polin &
COFN, 2012). Each of the individual risk factors (ROM greater than 24 hours, maternal
fever greater than or equal to 38ºC, and chorioamnionitis) was found to have poor
predictive value for EOS (Flidel-Rimon, Galstyan, Juster-Reicher, Rozin, & Shinwell,
2012). Puopolo et al. (2011) found that EOS risk decreased with gestational ages between
34 and 40 weeks, but after 40 weeks gestation EOS risk increased again. Additionally,
EOS risk increased with increasing time of ROM. Risk of EOS had a nearly linear
relationship for maternal temperatures between 99.5ºF and 100.4ºF, with a rapid
escalation in risk of EOS in neonates born to mothers with a temperature greater than
100.4ºF (Puopolo et al., 2011). The diagnosis of chorioamnionitis is the only risk factor
that leads to the treatment of well appearing, term neonates, an otherwise low EOS risk
segment of the population.
14

2.3. Chorioamnionitis
Chorioamnionitis is a complication of labor. The diagnosis implies inflammation
or infection of the fetal membranes (Higgins et al., 2016). The term chorioamnionitis
encompasses a heterogeneous group of infectious and inflammatory conditions with
varying degrees of severity and duration (Higgins et al., 2016). Higgins et al. (2016)
argue that the term chorioamnionitis inaccurately implies the presence of infection, is
outdated, and overused.
Braun et al. (2015) found that the rate of culture proven EOS was four per
thousand live births exposed to chorioamnionitis versus 0.61 per thousand live births in
all neonates. Exposure to chorioamnionitis increases the neonatal mortality rate from 0.81
to 1.40 per thousand live births (Malloy, 2014). Exposure to chorioamnionitis had a
positive predictive value of 7%, the highest of all maternal risk factors for EOS (FlidelRimon et al., 2012). In the 1980s culture proven neonatal EOS for neonates born to
mothers with chorioamnionitis was reported to be 80 to 200 per thousand live births
(Braun et al., 2015). Through the use of IAP the rate of culture proven EOS has been
reduced to between 12 and 30 per thousand live births (Braun et al., 2015). The risk of
infection after chorioamnionitis exposure is much higher in preterm neonates (NNT 6 to
21) than neonates with gestational ages equal to or greater than 35 weeks (NNT 80 to
210) (Benitz et al., 2015).
Diagnostic criteria for chorioamnionitis varies widely in practice (Higgins et al.,
2016). Strict diagnostic criteria for chorioamnionitis requires one to two additional
findings including intrapartum maternal fever (Benitz et al., 2015). Additional criteria for
15

the diagnosis of chorioamnionitis include maternal or fetal tachycardia, uterine
tenderness, foul odor of the amniotic fluid, or maternal leukocytosis (Verani et al., 2010).
The amount of risk conferred to a neonate born to a mother with a diagnosis of
chorioamnionitis depends on the criteria utilized at the time of diagnosis. The term
chorioamnionitis is imprecise and does not convey the severity of maternal or fetal illness
(Higgins et al., 2016). Escobar et al. (2000) used three levels of chorioamnionitis severity
to stratify neonatal risk of EOS. Neonatal infection rates increased with more rigorous
documentation of chorioamnionitis, infection rate for neonates born to mothers with
possible chorioamnionitis was 2.4%, probable chorioamnionitis 2.5%, and definite
chorioamnionitis 8.1% (Escobar et al., 2000). Flidel-Rimon et al. (2012) used strict
diagnostic criteria of chorioamnionitis plus one additional criteria more than fever to find
a positive predictive value for EOS of 7% when exposed to chorioamnionitis.
Conversely, using the less rigorous ICD-9 diagnosis criteria, the positive predictive value
was only 0.4% (95% CI 0.13 to 0.94) in a study of neonates with greater than or equal to
35 weeks gestation in Southern California (Braun et al., 2015). In a systematic review of
12 studies, the more strict diagnosis criteria of fever plus one additional finding conferred
twice the risk of EOS to neonates compared to the diagnosis made on fever alone (OR
4.0, OR 1.9) (Avila et al., 2015).
The antibiotic initiation rate for neonates born to mothers with a diagnosis of
chorioamnionitis ranged between 7 to 76% (Braun et al., 2015). The authors
hypothesized that these rates reflect a variation of attitudes toward EOS infection risk
incurred from a chorioamnionitis diagnosis. The number needed to treat to prevent one
16

culture proven EOS infection for neonates born to mothers with a formal diagnosis of
chorioamnionitis was 249, for fever alone the number need to treat to prevent one case of
culture proven EOS infection was 1,707 (Braun et al., 2015). In Malloy's (2014) analysis
of birth certificates in 2008, it was estimated it would take treatment of 1785 exposed
neonates to chorioamnionitis to prevent one death. The cost of providing care to prevent
one death was $10,424,400 in a level two NICU for administration of IV antibiotics
(Malloy, 2014). These figures lead Malloy (2014) to suggest refinement of the guidelines
regarding asymptomatic term infants exposed to maternal chorioamnionitis would appear
to need some refinement.
The CDC guidelines for neonatal management use maternal fever as a surrogate
for a diagnosis of chorioamnionitis (Verani et al., 2010). In clinical practice the diagnosis
of chorioamnionitis is made based on maternal fever, either defined as greater than
99.5°F (37.5°C) or 100.4°F (38°C) (Benitz et al., 2015; Malloy, 2014; Mukhopadhyay &
Puopolo, 2012).
The use of fever as a marker for chorioamnionitis and subsequent empiric
antibiotic treatment for suspected EOS in neonates is flawed. Higgins et al. (2016) posits
that maternal fever is not synonymous with chorioamnionitis as not all fevers are
infectious in origin. Fever can be caused by ambient temperature, epidural use,
dehydration, prostaglandins or other pyrogenic medications. Braun et al. (2015) found
that 60% of women with intrapartum fever did not meet an operational definition of
chorioamnionitis based on formal diagnostic criteria. Additionally, not all infectious
fevers put the neonate at risk as does chorioamnionitis. Maternal fevers may result from
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pyelonephritis, gastroenteritis or upper respiratory infection without increasing risk of
EOS in the neonate (Higgins et al., 2016).
The common practice of epidural pain control during labor appears to increase
risk of maternal fever and may be contributing to the overuse of empiric antibiotics in
neonates (Greenwell et al., 2012). As many as 70% of women receive epidural anesthesia
during labor (Mukhopadhyay, Eichenwald, & Puopolo, 2013). Greenwell et al. (2012)
estimated that more than 90% of fevers during labor are related to epidural use.
Intrapartum temperature greater than 100.4°F is more frequent (19.2%) in women who
receive epidural analgesia during labor compared to women who do not receive an
epidural (2.4%) (Greenwell et al., 2012). Thus, using fever as a marker for
chorioamnionitis in women with epidurals may contribute to the overtreatment of EOS in
neonates.
Current algorithms for the prevention and treatment of EOS recommend that all
neonates born to mothers with a diagnosis of chorioamnionitis be treated empirically with
broad spectrum antibiotics for 48 hours until infection can be ruled out. Cantey and Patel
(2014) estimated that upwards of 150,000 neonates in the United States receive empiric
antibiotics annually based on the diagnosis of maternal chorioamnionitis. There is a low
threshold for the clinical diagnosis of chorioamnionitis and subsequent neonatal treatment
decisions are not considered in the maternal diagnostic process (Higgins et al., 2016).
Reevaluation of the current guidelines centered on the diagnosis of chorioamnionitis is
warranted because of its limited predictive ability and imprecise diagnostic criteria
(Benitz et al., 2015).
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2.4. Treatment Guidelines for EOS
Clinical signs of EOS are nonspecific, and are similar to the symptoms of any
inflammatory process and are difficult to differentiate from noninfectious causes such as
the normal transition to postnatal life. Because there is no specific finding or test that
reliably identifies those with an EOS infection, treatment is broadly recommended to
ensure all infected neonates are treated. Such practices lead to treating a significant
number of uninfected infants (Taylor & Opel, 2012). New EOS incidence data, more
precise data on relative risk of each risk factor, and emerging information about the long
term health effects of antibiotics are reasons to reevaluate current treatment approaches
(Benitz et al., 2015).
The most recent revision of the CDC guidelines was published in 2010 and
recommends that all neonates symptomatic of EOS should have antimicrobial therapy
(Verani et al., 2010). Well appearing neonates born to women with a diagnosis of
chorioamnionitis are recommended to have empiric antimicrobial therapy (Verani et al.,
2010). The 2010 guidelines do not clearly define chorioamnionitis (Puopolo, 2012). The
lack of a consistent definition for chorioamnionitis limits the ability of the guidelines to
precisely determine which neonates should receive empiric treatment.
Mukhopadhyay et al. (2014) demonstrated that clarification to the definition of
inadequate IAP for GBS reduced use of empiric treatment for suspected EOS, without
increasing NICU admissions, signs of infection prior to discharge, or incidence of EOS.
This retrospective cohort study compared applied the original 2002 and revised 2010
CDC guidelines to a population of neonates with gestational ages greater than or equal to
19

36 weeks, had a sepsis evaluation in the first 48 hours of life, and were clinically
asymptomatic or well-appearing (n = 7226 or 14.7% of all births at the study center).
When applying the CDC 2010 guidelines to this sample, there would have been a
reduction of empiric antibiotic exposure from 7.24% to 5.21% of all neonates. The
decrease in neonates evaluated for EOS because of inadequate IAP (from 25.4% to less
than 1%) increased the proportion of well-appearing neonates evaluated for maternal
fever (from 70.4% to 93.3%) making exposure to fever the most frequent reason for
empiric antibiotic treatment in well appearing neonates. As a more precise definition of
inadequate IAP was able to reduce antibiotic exposure, clarification of the risk of EOS
conferred to neonates by chorioamnionitis exposure may also be able to safely reduce
empiric antibiotic therapy.
The AAP adopted treatment guidelines for suspected or proven EOS in 2012.
Polin and the COFN identified three challenges for clinicians; identifying neonates with a
high likelihood of EOS and promptly starting antimicrobial therapy; distinguishing highrisk neonates or neonates with clinical signs that should not be treated; and discontinuing
antibiotics when sepsis has been ruled out (Polin & COFN, 2012). In this guideline all
symptomatic neonates are to be treated. The only asymptomatic neonates with gestational
ages greater than 37 weeks that are recommended to receive broad spectrum empiric
antibiotic therapy are those born to a mother with a diagnosis of chorioamnionitis (Polin
& COFN, 2012). All other neonates greater than 37 weeks gestation with any other risk
factor are observed clinically and with laboratory tests before treatment is initiated. All
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empiric antibiotic treatment should be discontinued at 48 hours if the blood culture is
negative, lab data are normal, and the neonate remains well (Polin & COFN, 2012).
The AAP guideline has also been criticized for not offering a standard definition
of chorioamnionitis. As written chorioamnionitis is interchangeable with intrapartum
maternal fever, effectively making neonatal treatment decisions based on an imprecise
risk profile of maternal fever (Puopolo, 2012). Puopolo (2012) argues that combining all
preterm neonates into one group of less than 37 weeks gestation is too broad given the
different risks based on gestational age and birth weight. Puopolo (2012) contends that
the AAP guidelines take each risk factor for EOS in isolation and fail to consider the
relative contribution of each (Puopolo, 2012).

2.5. Consequences of Antibiotic Overuse
When used appropriately antibiotics are life-saving. In the past 75 years
antibiotic use has become a crucial component of global health (Laxminarayan et al.,
2016; Meropol & Edwards, 2015). Antibiotic use is not benign and has consequences on
an individual and population level. (Magsarili et al., 2015; Mukhopadhyay et al., 2013).
Antibiotic use contributes to the development of antibiotic resistant pathogens, superinfections, and research demonstrates links between antibiotic exposure and changes to
the gut microbiome influencing obesity, asthma, and allergy (Meropol & Edwards, 2015).
Antibiotic stewardship positively impacts quality of care, patient safety, clinical
outcomes, and resource utilization through monitoring and reducing unnecessary
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antibiotic using multi-disciplinary solutions (Goldman & Jackson, 2015; Patel & Saiman,
2010; Yang et al., 2016).
Antibiotic resistance is an emerging and major public health problem that is a
direct result of antibiotic overuse and selective pressure (Cotten, 2016; Laxminarayan et
al., 2013). Rates of antibiotic resistance are outpacing the discovery and development of
new antimicrobials (Magsarili et al., 2015). In a meta-analysis of 243 studies there was a
positive association between the rate of antibiotic consumption and the development of
antibiotic resistance (Bell, Schellevis, Stobberingh, Goossens, & Pringle, 2014).
Although there is no single solution to antibiotic resistance, one strategy is to remove or
reduce the selective pressure of antimicrobial exposure (Holmes et al., 2016). Antibiotic
stewardship slows antibiotic resistance through judicious use which decreases selective
pressure (Patel & Saiman, 2010). Antibiotic resistance prevention strategies such as
antibiotic stewardship are simple, inexpensive, and effective (Cailes, Vergnano,
Kortsalioudaki, Heath, & Sharland, 2015).
The NICU has been identified as a site for development and transmission of
antibiotic resistant bacteria because of the frequency of empiric antibiotic therapy (Cailes
et al., 2015). Additionally, neonates are particularly susceptible to the consequences of
resistant infections. Laxminarayan et al. (2016) estimate 214,500 global neonatal deaths
annually attributable to resistant pathogens.
The gut microbiome serves several essential roles: competition against the
proliferation of pathogens in the gut; metabolic functions of digestion, energy extraction,
breakdown of toxins, vitamin synthesis, and ion absorption; stimulating the
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differentiation of the epithelial cells of the intestine; and developing immune host
tolerance of food antigens (Cotten, 2016; Meropol & Edwards, 2015; Yang et al., 2016).
A diverse microbiome has been found to be health protective while low diversity is
associated with irritable bowel syndrome, necrotizing enterocolitis, and obesity (Yang et
al., 2016).
The human microbiome has a important window of colonization from birth
through approximately the first three years of life (Yallapragada, Nash, & Robinson,
2015). The most rapid stage of colonization is in the perinatal period (Meropol &
Edwards, 2015; Yallapragada et al., 2015). The composition of the microbiome is
influenced by mode of delivery (vaginal or surgical), antibiotic use, and method of
feeding (breast fed or bottle fed) (Yang et al., 2016). Vaginal delivery allows for vertical
transfer from mother to neonate. Neonates born vaginally have a microbiota that mirror
the composition of their mother's. Neonates born via cesarean-section have less diversity
in their microbiome and transfer is horizontal from the mother's skin and the environment
of the neonate (Meropol & Edwards, 2015; Yang et al., 2016). Antibiotic exposure
decreases the diversity of microbiota and delays colonization of commensal flora (Bailey
et al., 2014; Li, Wang, & Donovan, 2014; Yang et al., 2016). Formula feeding results in a
more diverse microbiome, however it appears to be of an unfavorable makeup with
higher tendency for atopy (Yang et al., 2016).
The timing of antibiotic exposure matters. Microbiota of neonates and children
are particularly vulnerable to disruption while the adult's microbiome is more stable
(Saari, Virta, Sankilampi, Dunkel, & Saxen, 2015; Trasande et al., 2013). Major
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taxonomic shifts happen as breast feed neonates are weaned (Meropol & Edwards, 2015),
while less dramatic changes are seen in formula fed neonates at weaning (Yang et al.,
2016). The major shifts in diet, growth, and the establishment of the microbiome that
occur in the first 24 months of life may make individuals more susceptible to the effects
of antibiotics during this critical developmental window (Bailey et al., 2014). Yang et al.
(2016) identified future research priorities of investigating the critical window of birth
through the first years of life, variables that influence colonization patterns, and the
makeup of a healthy microbiome.
Obesity. Obesity is a multifactorial condition, and identification of modifiable
risk factors is a key to reducing obesity rates (Magsarili et al., 2015). Alterations in the
microbiome have been attributed to alterations in metabolism (Yallapragada et al., 2015).
Sub-theraputic doses of antibiotics are used as growth promoters in animal farming (Saari
et al., 2015). The microbiome contributes to the energy extracted from the diet so a shift
in the composition of the microbiome may lead to altered microbial gene expression and
more efficient energy harvest (Saari et al., 2015). In studies of mice it has been found that
the timing of antibiotic administration is critical, there is a synergistic effect between
antibiotics and diet, and the obese metabolic phenotype can be transferred to germ free
mice via the microbiome (Cox et al., 2014).
A study of children in Philadelphia between 2001 and 2009, found that 69%
were exposed to antibiotics before 24 months of age (Bailey et al., 2014). When the
cohort was analyzed based on age at first antibiotic exposure, there was a greater effect
on obesity for earlier exposure, which was significant for broad-spectrum antibiotics
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(Bailey et al., 2014). A study of more than 11,000 children in the United Kingdom found
that antibiotic exposure in the first six months of life was associated with increased body
mass index at 38 months (overweight OR 1.22 at 38 months, p = 0.029; Trasande et al.,
2013). Trasande et al. concluded that early exposure to antibiotics may have a substantial
effect on population health, even if the individual effects are modest. In a cohort of
healthy Finnish children, antibiotic exposure was linked to a higher BMI (Saari et al.,
2015). There was a significant association between earlier antibiotic exposure (less than
six months old) and repeated courses of antibiotics. Bailey et al. (2014) suggested that
antibiotic treatment in the first 24 months of life might be a modifiable risk factor for
obesity, and treatment guidelines should limit antibiotic recommendations to situations
that have clearly demonstrated benefit and efficacy.
Allergy. The microbiome in the gastrointestinal tract functions to help mature
the immune system and achieve homeostasis through communication between intestinal
epithelium cells and the microbiome (Li, Wang, & Donovan, 2014). Li et al. (2014)
hypothesized that an imbalance between immune tolerance and active immune response
contributed to allergies and inflammatory bowel disease. The increase in allergic
diseases, particularly in industrialized countries, suggests a cause rooted in a western
lifestyle. Limited microbial exposure or antibiotic disruption to the microbiome early in
life appears to cause dysfunctional development of the immune system. A healthy
microbiome promotes balance between immune tolerance and response to help prevent
an abnormal immune reaction to benign substances.
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Asthma. The dysfunctional immune response and increase in allergies may have
a role in the increase of childhood asthma globally. In a nationwide cohort study of
American children, antibiotics in the first year of life were associated with transient
wheezing (beginning and resolving before age three; OR 2.0; 95% CI 1.9 to 2.2; p <
0.001), and persistent asthma (starting before age three and persisting through age four to
seven; OR 1.6; 95% CI, 1.5 to 1.7; p < 0.001) with a clear dose response (Ong et al.,
2014). Five or more courses of antibiotics doubled the odds of persistent asthma (OR 1.9;
95% CI 1.5 to 2.6; p < 0.001). Late onset asthma (onset after age three) tends not to be
related to allergic causes. In this study late onset asthma was not associated with early
antibiotic use, suggesting the association between asthma and antibiotic use is mediated
by intestinal microbial disruption and inappropriate immune response. The association of
asthma and antibiotics seem to be especially true in children without a family history of
asthma (Cotten, 2016).
Antibiotic administration can have effects beyond the direct physiological
impacts to the individual and population. Breast feeding is recognized as the optimal
feeding method in the first year of life. Mukhopadhyay, Lieberman, Puopolo, Riley, &
Johnson (2015) demonstrated a possible unintended consequence of antibiotic initiation.
An observational study of mothers intending to breastfeed, whose infants were well
appearing at birth, found that breast feeding was delayed and supplementation with
formula was increased when neonates were separated from their mothers for EOS
evaluation. The authors concluded that the effects of EOS evaluation and treatment could
be minimized by attempting breast feeding initiation before separation, or using better
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criteria to identify neonates with sufficient risk to warrant evaluation and treatment. This
study demonstrates the need to re-examine practices that have been previously considered
benign, and recognizes the need to revise potentially disruptive practices.

2.6. Proposed Model to Minimize Antibiotic Exposure in Neonates at Risk for EOS
The NEOS calculator was developed based on initial data from a nested case
control study by Puopolo et al. (2011) that used multivariate analyses and split validation
to divide a population of infants born at greater than or equal to 34 weeks gestation into
high and low risk cohorts based on their maternal intrapartum risk factors. Case subjects
had a culture confirmed bacterial infection less than 72 hours of age. Controls were
matched through random selection according to birth year and hospital. The incidence of
EOS in the entire study population was 0.58 per thousand live births. Through posterior
probability calculations it was determined that 6% of the population was high risk (4.2
per thousand live births) and 94% of the population was low risk (0.34 per thousand live
births) (Puopolo et al., 2011). Gestational age accounted for 17% of the predictive ability
of the NEOS calculator (Puopolo et al., 2011). Highest maternal temperature accounted
for 58% of the predictive ability of the model (Puopolo et al., 2011). Highest maternal
intrapartum temperature offers the advantage of being an objective measure instead of the
subjective and variable diagnosis of chorioamnionitis (Puopolo, 2012).
Escobar et al. (2014) proposed a quantitative risk stratification model of EOS
risk for newborns greater than or equal to 34 weeks gestational age based on risk factors.
In this model neonates are allocated into three risk categories based on objective data
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obtained during delivery; low, medium, and high risk. By evaluating and treating these
groups based on a more specific probability of EOS, they propose that clinicians would
be better able to guide care and provide treatment to those meeting criteria while avoiding
treatment for those that do not require it. In this study the majority (85%) of births met
low risk criteria. Low risk infants are recommended to receive routine observation based
on the EOS incidence estimated at 0.11 per thousand live births (NNT of 9370).
Equivocal presentation accounts for 11% of births. Neonates with an equivocal
presentation have an EOS rate of 1.31 per thousand live births and a NNT of 823. These
neonates are recommended to be followed closely and have a low threshold for treatment
should they become symptomatic or as indicated by abnormal laboratory results. The
final group, neonates with clinical illness, account for only 4% of births. These neonates
have an EOS rate of 5.57 per thousand live births and NNT of only 180 (Escobar et al.,
2014). With these neonates the authors recommend to begin immediate empiric
antibiotics pending a negative blood culture. By stratifying risk groups, clinicians are
better able to interpret data and determine clinical course of evaluation and treatment for
EOS.
Importantly, when applying the NEOS calculator, neonates are evaluated and
treated based upon continuous measures and duration of symptoms in contrast to previous
models which dichotomize data into symptomatic or asymptomatic, risk factors present
or absent (Escobar et al., 2014; Puopolo et al., 2011). Escobar's model is limited in it that
it only identifies neonates that require evaluation and treatment for EOS, it does not
determine what that evaluation and treatment should consist of. Applied nationally, this
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model could potentially reduce empiric antibiotic treatment by 80,000 to 240,000
neonates annually (Escobar et al., 2014).
Shakib et al. (2015) applied the NEOS calculator to a population of well
appearing neonates born to mothers with chorioamnionitis and gestational age greater
than or equal to 34 weeks. There was only one culture proven case of EOS (0.14%) and
was recommended to have empiric treatment indicating that the NEOS calculator would
not have missed any cases. In this sample use of the NEOS calculator would reduce the
portion of neonates receiving empiric antibiotic treatment to only 5% of the population
compared to the 62% that were actually treated (Shakib et al., 2015). The authors
concluded that use of the NEOS calculator would substantially reduce the number of
well-appearing neonates subjected to laboratory testing and empiric antibiotic exposure
based on the risk factor of maternal chorioamnionitis.
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CHAPTER 3: MANUSCRIPT
Background
Early onset sepsis (EOS) is a systemic bacterial infection that affects neonates
with onset in the first 72 hours following birth (Cotten, 2015; Polin & Committee on
Fetus and Newborn (COFN), 2012; Weston et al., 2011). Risk factors for EOS include
preterm delivery, maternal Group B Streptococcus (GBS) colonization, rupture of
membranes (ROM) greater than 18 hours, maternal fever, or diagnosis of
chorioamnionitis. There is no single test that can reliably rule in or rule out EOS. A
definitive diagnosis of EOS is made with a positive blood culture, however blood culture
can be unreliable related to high false negative rates from either inadequate volume for
testing or intrapartum antibiotic prophylaxis (IAP) use (Escobar et al., 2000).
Subsequently, clinicians have a greater index of suspicion for the diagnosis and a low
threshold for initiating treatment of suspected EOS in neonates with broad-spectrum
antibiotics based on maternal risk factors alone (Polin & COFN, 2012).
Chorioamnionitis is a major risk factor for EOS, associated with a two to three
fold increased risk of EOS in term neonates (Mukhopadhyay & Puopolo, 2012). Clinical
chorioamnionitis is diagnosed based on maternal signs during labor while histologic
chorioamnionitis is diagnosed through microscopic evaluation of the placenta after
delivery. Centers for Disease Control and Prevention (CDC) and American Academy of
Pediatrics (AAP) both recommend that all neonates born to a mother with a diagnosis of
chorioamnionitis be treated empirically with broad-spectrum antibiotics for 48 to 72
hours pending laboratory tests (Benitz et al., 2015; COFN, 2011; Verani et al., 2010).
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The current CDC and AAP treatment algorithms are based on risk factor
thresholds established prior to the widespread use of GBS testing and IAP (Puopolo et al.,
2011). Universal GBS screening and IAP have resulted in a 40% (Benitz et al., 2015;
Mukhopadhyay, Eichenwald, & Puopolo, 2013) to 85% reduction in incidence of EOS.
Antibiotics have potential adverse sequelae such as toxicities (Cotten, 2015;
Kiser et al., 2014), development of antibiotic resistant organisms (Smith et al., 2015), and
concerns about the effects on the neonate’s developing microbiome (Madan, Farzan,
Hibberd, & Karagas, 2012). The long term effects of antibiotics on the physiology of the
neonate's metabolism and immune programming are not fully understood leaving much
unknown (Ajslev, Andersen, Gamborg, Sørensen, & Jess, 2011). Further, Kiser et al.
(2014) found that infants receiving prolonged antibiotic therapy incur additional invasive
procedures such as lumbar puncture, central and peripheral lines, or umbilical
catheterization that lead to longer hospital stays and higher costs. Additionally, there are
psychological costs such as disruption of maternal bonding (Escobar et al., 2014) and
delayed initiation of breastfeeding (Mukhopadhyay, Lieberman, Puopolo, Riley, &
Johnson, 2015).
In an effort to improve management of neonates who receive empiric antibiotic
treatment for EOS, Puopolo and Escobar (2013) developed a Neonatal Early Onset Sepsis
(NEOS) calculator that uses the relative contributions of EOS risk factors to compute an
individualized risk profile. The NEOS calculator achieves a more precise management
strategy for individual neonates by using current epidemiologic data to assess population
risk and weighing the relative contribution of continuous data related to risk rather than
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dichotomized data. Implementation might reduce unnecessary antibiotic exposure
without compromising safety. Shakib, Buchi, Smith, and Young (2015) compared
antibiotic use between current guidelines and NEOS calculator. They found a reduction
of empiric antibiotic use of 80% between current practice and the recommendations of
the NEOS calculator. Further, Escobar et al. (2014) estimated that application of a model
that takes into account the relative risk factors of individual neonates could reduce
antibiotic exposure by 80,000 to 240,000 neonates in the United States annually.
Adoption of the NEOS calculator and risk stratification model to more precisely target
empiric treatment for suspected EOS has the potential to decrease unnecessary antibiotic
exposure, reduce health care costs, minimize antibiotic resistance, and lead to better
health outcomes for neonates.
Using the maternal diagnosis of clinical chorioamnionitis to determine neonatal
management can be problematic due to non-standard diagnosis criteria in current practice
(Benitz et al., 2015). In clinical practice, maternal fever alone is often used as a surrogate
for the diagnosis of chorioamnionitis (Benitz et al., 2015; Malloy, 2014; Mukhopadhyay
& Puopolo, 2012). Further, the rate of culture proven EOS in infants born to mothers with
clinical chorioamnionitis has been shown to be low; from 0.47% to 1.24% (Jackson et al.,
2004, 2012; Kiser et al., 2014). The inconsistent diagnostic criteria for chorioamnionitis
and recent studies that indicate a low rate of culture proven EOS in term neonates support
the need to reexamine current guidelines for the treatment of EOS in neonates (Benitz et
al., 2015; Brady & Polin, 2013; Polin & COFN, 2012).
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The purpose of this study was to analyze current practice and apply the NEOS
calculator to a population of term neonates born to mothers with a diagnosis of
chorioamnionitis at an academic medical center in the northeastern United States. Our
hypothesis was that application of the NEOS calculator (Kaiser Permanente, 2015)
would reduce the number of neonates that receive empiric antibiotic based of the risk
factor of maternal chorioamnionitis as compared to CDC guidelines, and current practice.

Methods
Research Design
A retrospective chart review was conducted to examine risk factors and
treatment of EOS in mothers with chorioamnionitis and their neonates at an academic
medical center in the northeastern United States. Puopolo et al. (2011) and Escobar et
al.'s (2014) NEOS calculator was applied to this data set to examine how an alternative
model would perform compared to current guidelines published by the CDC, the AAP,
and compared to current practice within the institution.
Inclusion criteria consisted of deliveries at the University of Vermont Medical
Center between January 1, 2014 and December 31, 2014 with a maternal diagnosis of
intrapartum or post partum chorioamnionitis and neonates with an estimated gestational
age greater than or equal to 37 weeks. Exclusion criteria were neonates with congenital
anomalies as defined by the Vermont Oxford Network (2013) and multiple gestation.
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Definitions
Chorioamnionitis was defined as a diagnosis documented in the maternal or
neonatal medical record. Post partum chorioamnionitis was defined as chorioamnionitis
diagnosed less than 12 hours following delivery. Broad-spectrum antibiotics were defined
as more than one antibiotic agent. Ampicillin or gentamicin alone were also considered
broad-spectrum when given to a GBS negative woman. Penicillin or ampicillin alone
administered to a GBS positive woman was considered to be a GBS specific antibiotic.
The following definitions are consistent with those used by the NEOS calculator
(Escobar et al., 2014). Neonatal clinical illness was defined as a five minute Apgar score
of less than five, neonatal encephalopathy, use of vasoactive drugs, clinical seizure,
continuous positive airway pressure, high flow nasal cannula, mechanical ventilation
outside of the delivery room, or need for supplemental oxygen to maintain saturation
greater than 90% for more than two hours.
Equivocal presentation was defined as an single vital sign category documented
as abnormal greater than four hours apart, or two vital sign categories each documented
as abnormal two hours apart in the first 12 hours of life.
Abnormal vital signs were defined as heart rate greater than or equal to 160
beats per minute, respiratory rate greater than or equal to 60 per minute, temperature
instability (greater than 100.4ºF or less than 97.5ºF), or respiratory distress (grunting,
flaring, retractions).
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Well appearing neonates were defined as not meeting the criteria for clinical
illness or equivocal presentation in the first 12 hours of life. In cases that were not clearly
in one clinical category, the neonate was classified into the more severe illness category.
In this study ruled out EOS was defined as neonates who received less than 72
hours (nine doses) of ampicillin under the assumption that the neonate had a reassuring
clinical presentation and normal labs at the time antibiotics were discontinued.
Study Procedures
Primary sampling was done by the Medical Center's Institute for Quality. A
search was conducted of the electronic health records (EHR) for ICD-9 codes (762.7,
658.40, 658.41, and 658.43) representing both maternal and neonatal diagnoses
associated with chorioamnionitis. An additional search was conducted through the OB
Net database of maternal discharge summaries using diagnosis or treatment of
chorioamnionitis. Mothers and neonates were paired to the corresponding EHR
depending on which health record was identified first. The second EHR was reviewed to
ensure the dyad met inclusion criteria.
The following data was abstracted from the EHR: estimated gestational age,
GBS status (positive, negative, or unknown), highest maternal intrapartum temperature,
antibiotic treatment of the mother and neonate (type and length of treatment), Apgar
scores at one and five minutes of life, and laboratory testing with results (including
complete blood count (CBC), C-reactive protein (CRP), and blood culture (BC)) from the
maternal and neonatal charts. Abstracted data was randomly spot verified during manual
review of charts by the principal investigator (PI).
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Manual chart review was conducted by the PI to collect data from the EHR that
were identified by OB Net alone, inclusion and exclusion criteria of all dyads, missing
data in the primary data set, duration of membrane rupture before delivery, and clinical
presentation of the neonate. ROM was calculated the nearest tenth of an hour based on
clinical notes of when ROM occurred relative to delivery time. Antibiotic administration
to the mother was categorized according to Puopolo and Escobar's NEOS calculator
(Escobar et al., 2014). Clinical presentation was determined using progress notes and
documented vital signs in the first 12 hours of life using the criteria described by Escobar
et al. (2014). Dyads that did not meet well defined inclusion criteria or clinical
presentation underwent a second review by an experienced neonatologist to determine
inclusion.
Data were entered into the online NEOS calculator using the CDC national
incidence of EOS (0.5/1000 live births) (Kaiser Permanente, 2015). Each neonate's risk
of EOS per thousand live births and the treatment recommendations based on clinical
presentation were recorded. Institutional review board approval was obtained prior to any
study procedures.
Data Analysis
Current practice was compared to Puopolo and Escobar's NEOS calculator
recommendations using binomial distribution and paired t-tests. McNemar's chi-square
test was used to determine significant differences between treatment rates in practice,
following strict interpretation of the CDC and AAP algorithms, and following
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recommendations from the NEOS calculator. Data was analyzed with IBM SPSS
Statistics 23 software, alpha was set a priori at the 0.05 level, two-sided.

Results
In 2014, there were 2,255 deliveries at the University of Vermont Medical
Center. The overall rate of chorioamnionitis for all gestational ages was 4%. The two
sampling methods identified 78 dyads. Six dyads were added to the sample from the OB
Net query alone. Of the 11 dyads identified by the Institute for Quality alone, 88% were
diagnosed with chorioamnionitis post partum and were included in the final sample. The
final sample consisted of 95 paired mother-neonate health records with the diagnosis of
chorioamnionitis.
Characteristics of the population entered in the NEOS calculator are included in
Table 1. The GBS status of all mothers was known; 22.1% (n = 21) were GBS positive
while 77.9% (n = 74) were GBS negative. The majority of women (52.6%, n = 50) did
not have IAP or IAP was less than two hours prior to birth. Broad-spectrum antibiotics
were given during labor greater than or equal to four hours prior to birth in 20% (n = 19)
of deliveries, 8.4% (n = 8) received broad-spectrum antibiotics two to 3.9 hours prior to
birth, and 19% (n = 18) had GBS specific antibiotics greater than or equal to two hours
prior to birth. Mean length of stay for neonates was 4.1 days (SD = 3.7). Blood cultures
were obtained in 83.1% (n = 79) of neonates. A single positive result grew
staphylococcus at 28 hours and was determined to be contamination.
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There were 18 (19%) neonates born to mothers diagnosed with chorioamnionitis
who would be treated with antibiotics due to signs of neonatal sepsis (equivocal
presentation or clinical illness) according to CDC and AAP guidelines. The remaining 77
(81%) neonates would be treated with antibiotics for chorioamnionitis exposure alone if
strictly following the recommendations of the CDC and AAP (Figure 1). Puopolo and
Escobar's NEOS calculator recommended empiric antibiotic treatment for 17 neonates
(0.18, 95% CI 0.12 to 0.29). 74 of 95 neonates were treated in current practice (0.78, 95%
CI 0.69 to 0.85).
Table 2 compares current practice to recommendations of Puopolo and Escobar's
NEOS calculator. A total of 34 (35.8%) neonates were managed congruently with the
NEOS calculator recommendations; 19 (20.0%) had no empiric treatment and 15 (15.8%)
had empiric treatment. There were 59 (62.1%) neonates that the calculator would not
recommend empiric treatment who received a total of 568 doses of ampicillin (mean 9.6
doses per neonate, 189 treatment days). They received a total of 194 doses of gentamicin
(mean 3.3 doses per neonate, 194 treatment days). There were two (2.2%) neonates that
the calculator recommended to treat based on risk factors that were not actually treated.
A safety analysis was done by comparing ampicillin administration stratified by
NEOS calculator recommendation (Figure 3). Of the 78 neonates that the calculator
recommends no treatment, 62 (79.5%) had less than nine doses of ampicillin and 16
(20.5%) had greater than nine doses of ampicillin. Of the 17 neonates that the calculator
recommends empiric antibiotic treatment 9 (52.9%) had fewer than nine doses of
ampicillin (including two neonates that did not receive any antibiotic treatment, contrary
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to the recommendations of the calculator) and eight (47.1%) had more than nine doses of
ampicillin.

Discussion
Our findings suggest that implementation of Puopolo and Escobar's NEOS
calculator would result in a 60% reduction in the number of neonates unnecessarily
treated with broad-spectrum antibiotics for suspected EOS due to maternal
chorioamnionitis. Considering only well appearing neonates, the NEOS calculator
recommendations would reduce empiric antibiotic use by 74% over current practice, and
99% over current CDC and AAP guidelines. The human microbiome plays an important
role in metabolic and immune functions, as well as endocrine and neural pathways (Yang
et al., 2016). Antibiotic use early in life can disrupt colonization decrease diversity of the
neonatal microbiome. Research linking antibiotic use to obesity, asthma, and allergies is
cause to rethink the threshold for initiating empiric antibiotics in neonates. Between the
three major influences on the microbiome (delivery mode, antibiotic exposure, and mode
of feeding) (Yang et al., 2016), antibiotic use is the modifiable risk factor most within
clinicians' control. Term neonates exposed to the diagnosis of clinical chorioamnionitis
may no longer meet the increased risk threshold to treat with empiric antibiotics when
examined with Puopolo and Escobar's NEOS calculator.
In a similar study, 65% of well appearing neonates were managed in practice
according to CDC and AAP guidelines and the application of Puopolo and Escobar's
infection probability calculator would reduce antibiotic treatment to only 12% of
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neonates (Shakib et al., 2015). In the study by Shakib et al. (2015) gestational ages
greater than or equal to 34 weeks were included. The higher gestational age range in our
study may demonstrate the reduced risk of sepsis with increasing gestational age.
Additionally, in our study GBS status of all mothers was known whereas Shakib et al.
(2015) reported that 62% had unknown GBS status. GBS status and treatment with IAP
are protective factors for EOS.
This study examined a population with documented chorioamnionitis that,
according to the CDC and AAP treatment algorithms, is at high enough risk to warrant
empiric treatment for EOS. The diagnosis of chorioamnionitis is problematic as clinicians
do not consistently follow strict diagnostic criteria in clinical practice and the diagnosis
of chorioamnionitis does not convey the degree of risk to mother or neonate (Higgins et
al., 2016). In practice, intrapartum fever is used as a surrogate for the diagnosis of
chorioamnionitis (Higgins et al., 2016). Many of the studies that linked increased risk of
EOS to chorioamnionitis used strict diagnostic criteria for chorioamnionitis (Benitz,
2015). We did not examine diagnostic criteria resulting in chorioamnionitis. It is possible
that the current algorithms for secondary prevention of EOS are appropriate when the
diagnosis of chorioamnionitis is made using strict diagnostic criteria. Until
chorioamnionitis is better defined and diagnosed, Puopolo and Escobar's infection
probability calculator eliminates one subjective criteria that may lead to antibiotic
overtreatment in neonates by using maximum intrapartum temperature as a continuous
variable to stratify risk.
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Current practice favors overtreatment helping to ensure no cases of EOS are
missed due to the potential morbidity and mortality of untreated sepsis. To examine the
safety of Puopolo and Escobar's NEOS calculator actual doses of ampicillin were
compared to calculator recommendations. The neonates that the calculator would not
recommend empiric antibiotic treatment for, but received more than nine doses of
ampicillin, are an area of safety concern as missed cases have harmful sequelae if
antibiotics are not initiated promptly. If these neonates were treated based on evolving
clinical presentation instead of empiric treatment for risk factors, antibiotic stewardship is
improved, but there is a possibility of delayed treatment. Clear empiric antibiotic savings
come from the neonates that the NEOS calculator would not treat and had less than or
equal to nine doses of ampicillin. A quarter of these neonates were not treated at all,
which could be case studies for potential outcomes of the NEOS calculator if used in
practice. If the neonates who were ruled out for EOS were managed with the NEOS
calculator recommendation not to be treated, 42 fewer children would be at risk for the
adverse effects of antibiotics and 273 fewer doses of ampicillin would be administered.
Reviewing cases that antibiotics were continued for a full course would offer more
insight into the clinical reasons antibiotics were continued and examine if there are
potential savings by discontinuing empiric treatment appropriately. The neonates that the
NEOS calculator recommends to treat had risk factors that warranted empiric antibiotics,
but the neonate was well enough at 48 to 72 hours to discontinue treatment. In this group
the risk is high enough to justify empiric antibiotic use. The neonates that the NEOS
calculator recommends to treat and had greater than nine doses of ampicillin are
41

conclusively ill. Despite negative blood cultures the risk factors and presentation of the
neonate indicated treatment according to the NEOS calculator and in practice treatment
was continued. The use of Puopolo and Escobar's infection probability calculator appears
to offer antibiotic exposure reduction without compromising safety for neonates.
This study is limited by its homogenous population. Black neonates are
disproportionately affected by EOS and have amongst the highest incidence and fatality
rates (Weston, 2011). Our study population was predominantly non-black and all term,
which has amongst the lowest incidence and fatality rates (Weston, 2011). Although we
examined a population least impacted by EOS, perhaps this is a population best targeted
for antibiotic reduction. We did not follow neonates after initial discharge. It is not
known if there were hospital readmissions for infection or if neonates suffered any
adverse outcomes related to antibiotic treatment.

Conclusion
The potential adverse effects of antibiotics demonstrate the need to raise the
threshold for initiating treatment. Until there are reliable tests to improve the detection of
EOS, algorithms must be relied on to assist management decisions. Puopolo and
Escobar's NEOS calculator appears to offer advantages over current models without
compromising safety in term neonates. Term neonates (greater than or equal to 37 weeks)
are at decreased risk for EOS compared to preterm neonates (Benitz et al., 2015), and
therefore appears to be a population that can afford to be observed without empiric
antibiotic treatment.
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Table 1: Population characteristics. Population characteristics entered into the NEOS
calculator.

Minimum

Maximum

Mean

Estimated
Gestational Age

37 weeks

42 weeks 1 day

40 weeks 2 days

Maximum
Intrapartum
Temperature

97.0°F

102.7°F

100.7°F

Rupture of
Membranes

0 hours

77 hours

15.6 hours

Group B
Streptococcus
Status
Intrapartum
Antibiotics

Positive: 22.1% (21)
Negative: 77.9% (74)

Broad spectrum antibiotics > 4 hrs prior to birth: 20% (20)
Broad spectrum antibiotics 2-3.9 hrs prior to birth: 8.4% (8)
GBS specific antibiotics > 2 hrs prior to birth: 19% (18)
No antibiotics or any antibiotics < 2 hrs prior to birth:
52.6% (50)
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CDC/AAP
Signs of neonatal
sepsis?

Yes

Treat:
n = 18

Infection
Probability
Calculator

Treat:
n = 16

Do not
treat:
No

n=2

Maternal
chorioamnionitis?
Treat:
Yes

Treat:
n = 77

n=1

Actual
Treatment

> 9 amp:
n=8
< 9 amp:
n=7
No
antibiotics: n
=1
> 9 amp:
n=0
< 9 amp:
n=1
No
antibiotics: n
=1
> 9 amp:
n=0
< 9 amp:
n=0
No
antibiotics: n
=1
> 9 amp:
n = 16

Do not
treat:

< 9 amp:
n = 42

n = 76

No
antibiotics: n
= 18

Interpretation

Illness- treatment
needed
Justifiable empiric
antibiotics, but sepsis
is ruled out
Sepsis not suspected
enough for treatment
Potential sepsis cases
missed by the
calculator
Justifiable empiric
antibiotics, but sepsis
is ruled out
Sepsis not suspected
enough for treatment
Illness- treatment
needed
Justifiable empiric
antibiotics, but sepsis
ruled out
Sepsis not suspected
enough for treatment
Potential sepsis cases
missed by the
calculator
Sepsis ruled out,
potential empiric
antibiotics savings
Sepsis not suspected
enough for treatment

Figure 1. Comparison of how each treatment scheme would manage the population.
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Table 2. NEOS calculator recommendations.
NEOS calculator
recommendations
for antibiotics

Actual treatment with antibiotics
No treatment

Empiric antibiotic
treatment

Total

No treatment

19*

59**

78

Empiric antibiotic

2***

15*

17

21

74

95

Total

Note: Puopolo and Escobar's infection probability calculator would recommend no
empiric antibiotic treatment for 78 (82.22%) neonates. 74 (77.89%) neonates were treated
with empiric antibiotics.
*34 (35.79%) neonates were managed congruently with the NEOS calculator
recommendations; 19 (20%) no empiric treatment; 15 (15.79%) to treat empirically.
** 59 (62.11%) neonates that the calculator would not recommend to treat received a
total of 568 doses of ampicillin (mean 9.63 doses per neonate) representing 189.33
treatment days. They received a total of 194 doses of gentamicin (mean 3.29 doses per
neonate) representing 194 treatment days.
***There were two (2.22%) neonates that the calculator recommended to treat based on
risk factors that were not actually treated.
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Table 3. Safety analysis.
Actual ampicillin administration
Calculator
recommendation

< 9 doses of ampicillin

> 9 doses of ampicillin

Total:

No antibiotic
treatment

62 (65.26%)*

16 (16.84%)**

78

Empiric antibiotic
treatment

9 (9.47%)***

8 (8.42%)****

17

71

24

95

Total:

Note: Nine doses of ampicillin indicates a cut point of 72 hours of treatment. According
to CDC and AAP guidelines a well appearing, term neonate, with a negative blood
culture should not be treated longer than 48 to 72 hours.
*Clear empiric antibiotic savings: NEOS calculator would not treat and had less than or
equal to nine doses of ampicillin. Of these 62 neonates, 19 were not treated with any
ampicillin. The remaining 43 in this group had sepsis ruled out in 48 to 72 hours and
ampicillin was discontinued. These neonates received 273 doses of ampicillin.
**Safety concern or potential missed cases: 16 neonates that the calculator would not
recommend empiric antibiotic treatment, but received more than nine doses of ampicillin.
These neonates could represent an area of with harmful sequelae if antibiotics are not
initiated promptly.
***Justifiable empiric antibiotics: Antibiotics were initiated, but the neonate was well
enough at 48 to 72 hours to discontinue treatment (52.9%, n = 9).
****Conclusively ill: Empiric treatment recommended by the NEOS calculator based on
risk factors and had greater than nine doses of ampicillin based on concerning lab results
or clinical presentation of the neonate 47.1% (n = 8).
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Sepsis risk at birth estimated from maternal risk factors
Low
Medium
High
Clinical
Presentation

Well Appearing
n = 77

Equivocal
Presentation
n=9

(< 0.65)

(0.65 - 1.54)

(≥ 1.54)

n = 41

n = 42

n = 12

Continued

Observe and

Treat Empirically

Observation

Evaluate

n=9

n = 39

n = 29

88.89% were

61.54% were

89.66% were

treated

treated

treated

Observe and

Treat Empirically

Treat Empirically

Evaluate

n=5

n=2

n=2

80% were treated

100% were treated

Treat Empirically

Treat Empirically

Treat Empirically

n=0

n=8

n=1

N/A

100% were treated

100% were treated

50% were treated
Clinical Illness
n=9

Figure 2. Proposed and actual population management.
Note. When the sepsis risk score generated by Puopolo and Escobar's infection probably
calculator is used to determine treatment recommendations for the population are as
follows: continued observation for 41.05% (n = 39) of the population, observe and
evaluate 32.63% (n = 31), and empiric antibiotic treatment for 26.63% (n = 25). Actual
treatment of each subpopulation is indicated in italics.
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